These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Pretreatment with different loading doses of clopidogrel influences P-selectin levels in patients undergoing percutaneous coronary intervention: results from the ARMYDA-2 (antiplatelet therapy for reduction of myocardial damage during angioplasty) SELECT substudy. Patti G; Chello M; Pasceri V; Colonna D; Colonna G; Pepe LL; Montinaro A; Covino E; Di Sciascio G J Cardiovasc Med (Hagerstown); 2011 Mar; 12(3):151-6. PubMed ID: 21085001 [TBL] [Abstract][Full Text] [Related]
24. The influence of bisoprolol dose on ADP-induced platelet aggregability in patients on dual antiplatelet therapy. Ignjatovic VS; Petrovic N; Miloradovic V; Ignjatovic S; Cokanovic V; Grdinic A; Simic I; Petrovic I; Nikolic S; Andjelkovic A; Paramentic D; Ignjatovic S Coron Artery Dis; 2010 Dec; 21(8):472-6. PubMed ID: 20861734 [TBL] [Abstract][Full Text] [Related]
25. Epistaxis as the reason for premature discontinuation of clopidogrel after percutaneous coronary angioplasty with stent implantation. Jura-Szołtys E; Chudek J Kardiol Pol; 2011; 69(8):817-23. PubMed ID: 21850627 [TBL] [Abstract][Full Text] [Related]
26. [Is stent thrombosis the new Achilles heel of interventional cardiology? State of the Art clinical trials, causes and approaches for prevention]. Grumann T; Diehl P; Bode C; Moser M Hamostaseologie; 2007 Dec; 27(5):344-50. PubMed ID: 18060244 [TBL] [Abstract][Full Text] [Related]
27. Very late stent thrombosis after dual antiplatelet therapy discontinuation in a patient with a history of acute stent thrombosis. Bhatt SH; Hauser TH Ann Pharmacother; 2008 May; 42(5):708-12. PubMed ID: 18381843 [TBL] [Abstract][Full Text] [Related]
32. Tirofiban use with clopidogrel and aspirin decreases adverse cardiovascular events after percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials. Sethi A; Bahekar A; Doshi H; Bhuriya R; Bedi U; Singh S; Khosla S Can J Cardiol; 2011; 27(5):548-54. PubMed ID: 21871775 [TBL] [Abstract][Full Text] [Related]
33. Risk and management of upper gastrointestinal bleeding associated with prolonged dual-antiplatelet therapy after percutaneous coronary intervention. Tan VP; Yan BP; Kiernan TJ; Ajani AE Cardiovasc Revasc Med; 2009; 10(1):36-44. PubMed ID: 19159853 [TBL] [Abstract][Full Text] [Related]
34. Conversation with an expert. Plavix: what you need to know. O'Gara P Harv Heart Lett; 2011 Jan; 21(5):3. PubMed ID: 21322911 [No Abstract] [Full Text] [Related]
35. Competing pharmacological strategies during PCI-analysis of a prematurely terminated trial. Kimmelstiel C Catheter Cardiovasc Interv; 2011 Jun; 77(7):1010-1. PubMed ID: 21598352 [No Abstract] [Full Text] [Related]
36. [Warfarin combined with blood platelet inhibition]. Vik-Mo H Tidsskr Nor Laegeforen; 2011 Feb; 131(3):252-3. PubMed ID: 21304575 [TBL] [Abstract][Full Text] [Related]
37. Stent thrombosis in 2008: definition, predictors, prognosis and treatment. Lemesle G; Delhaye C; Bonello L; de Labriolle A; Waksman R; Pichard A Arch Cardiovasc Dis; 2008; 101(11-12):769-77. PubMed ID: 19059572 [TBL] [Abstract][Full Text] [Related]
38. Percutaneous coronary intervention: assessing coronary vascular risk associated with bare-metal and drug-eluting stents. Spinler SA Am J Manag Care; 2009 Mar; 15(2 Suppl):S42-7. PubMed ID: 19355808 [TBL] [Abstract][Full Text] [Related]